Seqens Group, an integrated developer and manufacturer of active pharmaceutical ingredients (APIs) and intermediates has opened Seqens Boston R&D Center, a state-of-the-art, 15,000 sq ft R&D centre in Devens, MA. Serving as one of the company’s global centres of excellence, the new facility will provide advanced capabilities for the discovery and development of new drugs and therapeutics. 

The company invested $5 million in the new facility that features advanced technologies, equipment and design, adhering to the highest levels of quality, sustainability and safety. The new lab replaces an older, smaller R&D facility in Devens, and all current employees have moved to the new lab. Seqens plans to double the number of scientists there by 2026.

The new R&D Center expands project flow, enhances the quality and accelerates the development of APIs and excipients, including lipids used for the manufacture of RNA vaccines for COVID. It will serve as the North American flagship for Seqens’ global R&D network – consisting of 10 R&D centres across Europe and North America to support pharmaceutical customers from the preclinical phases through to commercialisation. 

The investment in Devens significantly strengthens the company’s US operations – which also include contract development and manufacturing facilities in Newburyport, MA. The official opening comes a year after SK Capital became a majority shareholder in the group, merging it with its portfolio company Wavelength Pharmaceuticals to create one of the largest and most diversified CDMOs.